Monoclonal Antibody to Serpin B3 (SERPINB3)
| Code | Size | Price |
|---|
| MAB372Hu24-20ul | 20ul | £89.00 |
Quantity:
| MAB372Hu24-100ul | 100ul | £167.00 |
Quantity:
| MAB372Hu24-200ul | 200ul | £225.00 |
Quantity:
| MAB372Hu24-1ml | 1ml | £518.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
SCCA1; T4-A; Serpin Peptidase Inhibitor,Clade B(ovalbumin),Member 3; Serpin B3
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG2b Kappa
Immunogen:
RPB372Hu01-Recombinant Serpin B3 (SERPINB3)
Item Name:
Serpin B3
Potency (Clone Number):
C1
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Squamous Cell Carcinoma Antigen 1 (SCCA1) | RPB372Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||